Actelion restarts takeover talks with original suitor

22 December 2016

In what could almost be called a Machiavellian twist, Swiss company Actelion (SIX: ATLN) seems to have spurned a second takeover suitor and gone back to the US the healthcare giant that started a spurned acquisition approach which was confirmed just a week ago.

Shares of Actelion were up nearly 7% at 230.00 Swiss francs ($224.27) in early trading this morning.

While speculation was rife that France’s Sanofi (Euronext: SAN) had stepped into the breach to buy the company, in a terse statement released late Wednesday, Actelion, Europe’s biggest biotech with a market value of around $22.5 billion, announced that it has entered into “exclusive negotiations” with Johnson & Johnson (NYSE: JNJ) regarding a possible strategic transaction. At the time J&J ended talks, Actelion said that it was “engaged in discussions with another party,” without saying who, leading to the Sanofi speculation, with any such specific discussion neither confirmed nor denied by the concerned parties.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK